COVID-19 Vaccine Impact on Interleukin Inhibitors Market Is Forecast To Reach $74.6 Billion By 2026

The global interleukin inhibitors market size is expected to reach USD 74.6 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 17.4% over the forecast period. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB’s bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn’s & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).

To request a sample copy or view summary of this report, click the link below:
www.grandviewresearch.com/industry-analysis/interleukin-inhibitors-market

Further key findings from the report suggest:

  • Psoriatic arthritis and IBD are projected to register fastest growth through to 2026
  • IL-17 is likely to overtake IL-23 as the leading type by 2026
  • IL-5 inhibitors for asthma to witness strong growth in the near future
  • Asia Pacific is expected to exhibit the fastest regional growth
  • Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration
(Visited 1 times, 1 visits today)

Comments

comments

You may also like...